Publicaciones en colaboración con investigadores/as de Hospital Clinic Barcelona (74)

2024

  1. Characterization of hospitalized patients with acute kidney injury associated with COVID-19 in Spain: Renal replacement therapy and mortality. FRA-COVID SEN Registry Data

    Nefrologia, Vol. 44, Núm. 4, pp. 527-539

  2. Efficacy and safety of biological treatment for inflammatory bowel disease in elderly patients: Results from a GETECCU cohort

    Gastroenterologia y Hepatologia

  3. Interobserver Reliability and Sensitivity to Change of a Composite Ocular Inflammatory Activity Index: UVEDAI©

    Ophthalmology and Therapy, Vol. 13, Núm. 6, pp. 1669-1682

  4. Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry

    Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 5, pp. 604-612

  5. Omicron SARS-CoV-2 infection management and outcomes in patients with hematologic disease and recipients of cell therapy

    Frontiers in Oncology, Vol. 14

  6. Screening and diagnosis of primary aldosteronism. Consensus document of all the Spanish Societies involved in the management of primary aldosteronism

    Endocrine, Vol. 85, Núm. 1, pp. 99-121

  7. T-Cell Immune Responses in Newborns and Long-Term Sequelae in Congenital Cytomegalovirus Infection (CYTRIC Study)

    Journal of Pediatrics, Vol. 272

  8. Trends in imported infections among migrants and travellers to Spain: a decade of analysis through the +Redivi network (2012–2022)

    Journal of Travel Medicine, Vol. 31, Núm. 6

2023

  1. Correction to: Validation of UVEDAI: An Index for Evaluating the Level of Inflammatory Activity in Uveitis (Ophthalmology and Therapy, (2023), 12, 2, (1045-1055), 10.1007/s40123-023-00654-8)

    Ophthalmology and Therapy

  2. Dual latent tuberculosis screening with tuberculin skin tests and QuantiFERON-TB assays before TNF-α inhibitor initiation in children in Spain

    European Journal of Pediatrics, Vol. 182, Núm. 1, pp. 307-317

  3. Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 17, Núm. 1, pp. 83-91

  4. Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated with Internal Fistulizing Disease: BIOSCOPE Study from GETECCU

    American Journal of Gastroenterology, Vol. 118, Núm. 6, pp. 1036-1046

  5. One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients

    Blood Cancer Journal, Vol. 13, Núm. 1

  6. POS0652 Interobserver Reliability and Sensitivity to Change of a Composite Ocular Inflammatory Activity Index: Uvedai

    Annals of the Rheumatic Diseases, Vol. 82, Núm. Suppl 1, pp. 604-605

  7. Validation of UVEDAI: An Index for Evaluating the Level of Inflammatory Activity in Uveitis

    Ophthalmology and Therapy, Vol. 12, Núm. 2, pp. 1045-1055

2022

  1. Early procalcitonin to predict mortality in critically ill COVID-19 patients: a multicentric cohort study

    Minerva Anestesiologica, Vol. 88, Núm. 4, pp. 259-271

  2. Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients

    Frontiers in Medicine, Vol. 9

  3. Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry

    Journal of Clinical Medicine, Vol. 11, Núm. 2

  4. Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)

    Journal of Clinical Medicine, Vol. 11, Núm. 24

2021

  1. Autoantibody screening in Guillain–Barré syndrome

    Journal of Neuroinflammation, Vol. 18, Núm. 1